NURIX THERAPEUTICS, INC. Earnings Per Share, Basic and Diluted
NURIX THERAPEUTICS, INC. (NRIX) reported Earnings Per Share, Basic and Diluted of -$0.95 per share for the 3-month period ending 2022-02-28, per its 10-Q filed 2022-04-08.
Discontinued › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2022-04-08
- NURIX THERAPEUTICS, INC. earnings per share, basic and diluted for the quarter ending 2022-02-28 was -$0.95.
- NURIX THERAPEUTICS, INC. earnings per share, basic and diluted for the quarter ending 2021-08-31 was -$0.65.
- NURIX THERAPEUTICS, INC. earnings per share, basic and diluted for the quarter ending 2021-02-28 was -$0.63.
- NURIX THERAPEUTICS, INC. earnings per share, basic and diluted for the quarter ending 2020-11-30 was -$0.51.
- NURIX THERAPEUTICS, INC. earnings per share, basic and diluted for fiscal 2021 was -$2.73.
- NURIX THERAPEUTICS, INC. earnings per share, basic and diluted for fiscal 2020 was -$2.76.
- NURIX THERAPEUTICS, INC. earnings per share, basic and diluted for fiscal 2019 was -$6.59.
| Period end | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 3 month as first filed | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 9 month as first filed | Earnings Per Share, Basic and Diluted 12 month |
|---|---|---|---|---|---|---|
| 2022-02-28 | -$0.95 10-Q · filed 2022-04-08 | |||||
| 2021-11-30 | -$2.73 10-K · filed 2022-01-28 | |||||
| 2021-08-31 | -$0.65 10-Q · filed 2021-10-14 | -$1.88 10-Q · filed 2021-10-14 | ||||
| 2021-02-28 | -$0.63 10-Q · filed 2022-04-08 | |||||
| 2020-11-30 | -$0.51 10-K · filed 2021-02-16 | -$2.76 10-K · filed 2022-01-28 | ||||
| 2020-08-31 | -$1.09 10-Q · filed 2021-10-14 | -$0.59 10-Q · filed 2020-10-14 | -$2.90 10-Q · filed 2021-10-14 | -$0.84 10-Q · filed 2020-10-14 | ||
| 2020-05-31 | $2.03 10-K · filed 2021-02-16 | -$1.32 derived: net income ÷ weighted average shares · filed 2021-07-13 | ||||
| 2020-02-29 | -$3.50 10-Q · filed 2021-04-13 | |||||
| 2019-11-30 | -$3.55 10-K · filed 2021-02-16 | -$6.59 10-K · filed 2022-01-28 | ||||
| 2019-08-31 | -$0.66 10-K · filed 2021-02-16 | -$2.38 10-Q · filed 2020-10-14 | ||||
| 2019-05-31 | -$0.89 10-K · filed 2021-02-16 | |||||
| 2019-02-28 | -$0.84 10-K · filed 2021-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |